Erlanson DA - Search Results

1

Optimization of novel reversible Bruton's tyrosine kinase inhibitors identified using Tethering-fragment-based screens.

Hopkins BT, Bame E, Bell N, Bohnert T, Bowden-Verhoek JK, Bui M, Cancilla MT, Conlon P, Cullen P, Erlanson DA, Fan J, Fuchs-Knotts T, Hansen S, Heumann S, Jenkins TJ, Marcotte D, McDowell B, Mertsching E, Negrou E, Otipoby KL, Poreci U, Romanowski MJ, Scott D, Silvian L, Yang W, Zhong M. Hopkins BT, et al. Among authors: erlanson da. Bioorg Med Chem. 2019 Jul 1;27(13):2905-2913. doi: 10.1016/j.bmc.2019.05.021. Epub 2019 May 14. Bioorg Med Chem. 2019. PMID: 31138459

2

Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based drug design.

Choong IC, Lew W, Lee D, Pham P, Burdett MT, Lam JW, Wiesmann C, Luong TN, Fahr B, DeLano WL, McDowell RS, Allen DA, Erlanson DA, Gordon EM, O'Brien T. Choong IC, et al. Among authors: erlanson da. J Med Chem. 2002 Nov 7;45(23):5005-22. doi: 10.1021/jm020230j. J Med Chem. 2002. PMID: 12408711

3

Discovery of a new phosphotyrosine mimetic for PTP1B using breakaway tethering.

Erlanson DA, McDowell RS, He MM, Randal M, Simmons RL, Kung J, Waight A, Hansen SK. Erlanson DA, et al. J Am Chem Soc. 2003 May 14;125(19):5602-3. doi: 10.1021/ja034440c. J Am Chem Soc. 2003. PMID: 12733877

4

Tethering: fragment-based drug discovery.

Erlanson DA, Wells JA, Braisted AC. Erlanson DA, et al. Annu Rev Biophys Biomol Struct. 2004;33:199-223. doi: 10.1146/annurev.biophys.33.110502.140409. Annu Rev Biophys Biomol Struct. 2004. PMID: 15139811 Review.

5

Fragment-based drug discovery.

Erlanson DA, McDowell RS, O'Brien T. Erlanson DA, et al. J Med Chem. 2004 Jul 1;47(14):3463-82. doi: 10.1021/jm040031v. J Med Chem. 2004. PMID: 15214773 Review. No abstract available.

6

Allosteric inhibition of protein tyrosine phosphatase 1B.

Wiesmann C, Barr KJ, Kung J, Zhu J, Erlanson DA, Shen W, Fahr BJ, Zhong M, Taylor L, Randal M, McDowell RS, Hansen SK. Wiesmann C, et al. Among authors: erlanson da. Nat Struct Mol Biol. 2004 Aug;11(8):730-7. doi: 10.1038/nsmb803. Epub 2004 Jul 18. Nat Struct Mol Biol. 2004. PMID: 15258570

7

Making drugs on proteins: site-directed ligand discovery for fragment-based lead assembly.

Erlanson DA, Hansen SK. Erlanson DA, et al. Curr Opin Chem Biol. 2004 Aug;8(4):399-406. doi: 10.1016/j.cbpa.2004.06.010. Curr Opin Chem Biol. 2004. PMID: 15288250 Review.

8

Allosteric inhibition of PTP1B activity by selective modification of a non-active site cysteine residue.

Hansen SK, Cancilla MT, Shiau TP, Kung J, Chen T, Erlanson DA. Hansen SK, et al. Among authors: erlanson da. Biochemistry. 2005 May 31;44(21):7704-12. doi: 10.1021/bi047417s. Biochemistry. 2005. PMID: 15909985

9

Fragment-based ligand discovery meets phage display.

Erlanson DA. Erlanson DA. ACS Chem Biol. 2007 Dec 21;2(12):779-82. doi: 10.1021/cb700240b. ACS Chem Biol. 2007. PMID: 18154264

10

Discovery of an Aurora kinase inhibitor through site-specific dynamic combinatorial chemistry.

Cancilla MT, He MM, Viswanathan N, Simmons RL, Taylor M, Fung AD, Cao K, Erlanson DA. Cancilla MT, et al. Among authors: erlanson da. Bioorg Med Chem Lett. 2008 Jul 15;18(14):3978-81. doi: 10.1016/j.bmcl.2008.06.011. Epub 2008 Jun 10. Bioorg Med Chem Lett. 2008. PMID: 18579375

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

46 results

Search Page

Filters